Home » Stocks » NVIV

Invivo Therapeutics Holdings Corp. (NVIV)

Stock Price: $0.572 USD -0.013 (-2.14%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $0.572 +0.001 (0.09%) Nov 27, 4:47 PM

Stock Price Chart

Key Info

Market Cap 12.10M
Revenue (ttm) n/a
Net Income (ttm) -10.25M
Shares Out 21.17M
EPS (ttm) -3.82
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $0.572
Previous Close $0.584
Change ($) -0.013
Change (%) -2.14%
Day's Open 0.581
Day's Range 0.570 - 0.584
Day's Volume 627,758
52-Week Range 0.498 - 11.990

More Stats

Market Cap 12.10M
Enterprise Value 5.30M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 21.17M
Float n/a
EPS (basic) -11.41
EPS (diluted) -3.82
FCF / Share -1.95
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 153,853
Short Ratio 0.08
Short % of Float n/a
Beta 1.79
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 1.55
Revenue n/a
Operating Income -9.65M
Net Income -10.25M
Free Cash Flow -9.52M
Net Cash 6.80M
Net Cash / Share 0.32
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -55.67%
ROE -130.92%
ROIC -492.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$37.50*
Low
37.5
Current: $0.572
High
37.5
Target: 37.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue----------
Operating Income-11.50-12.77-24.59-24.06-22.40-17.84-19.01-12.78-8.66-3.40
Net Income-11.83-23.42-26.75-23.44-33.31-18.35-38.764.66-34.73-7.91
Shares Outstanding0.340.170.040.040.040.030.020.020.020.01
Earnings Per Share-35.28-140.81-608.76-570.06-945.10-622.56-1,575.16195.02-2,010.20-720.07
Operating Cash Flow-10.31-12.31-19.68-16.74-16.33-15.28-14.91-10.20-7.43-2.65
Capital Expenditures-0.01-0.07-0.07-0.11-0.01-0.05-0.75-2.14-0.28-0.15
Free Cash Flow-10.33-12.38-19.75-16.85-16.33-15.33-15.66-12.35-7.71-2.79
Cash & Equivalents6.6116.6613.2733.4020.5613.8814.5813.434.918.96
Total Debt1.310.100.851.281.671.942.021.610.20-
Net Cash / Debt5.2916.5612.4232.1318.8911.9412.5711.814.718.96
Assets9.3318.3814.0534.7821.7916.6917.1016.065.709.38
Liabilities3.742.273.945.844.8610.784.2118.3736.8611.23
Book Value5.5816.1110.1128.9516.935.9212.89-2.31-31.16-1.85
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Invivo Therapeutics Holdings Corp.
Country United States
Employees 6
CEO Richard Toselli

Stock Information

Ticker Symbol NVIV
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NVIV

Description

InVivo Therapeutics Holdings, a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for the implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.